GRAIL reflects on Juneteenth and healthcare inequities
Systemic barriers, not biology, cause higher cancer mortality among Black patients.
See the latest news and media coverage for GRAIL. We track all announcements, press releases, and industry mentions in real time, all in one place.
Multi-cancer early detection company
grail.comLast updated
In short: GRAIL completed its spin-off from Illumina and transitioned to a standalone public company while facing a securities fraud class action lawsuit.
Systemic barriers, not biology, cause higher cancer mortality among Black patients.
Ann's participation in the NHS-Galleri trial led to early diagnosis of stage III bowel cancer, with 82% sensitivity.
The episode features Dr. Scout from the National LGBT Cancer Network addressing barriers to screening and care.
Quoting Dr. Nima Nabavizadeh on multi-cancer early detection potential.
Grail's Galleri blood test missed its primary endpoint in the massive NHS-Galleri trial yet delivered a 14% reduction in stage IV cancers and quadrupled screen-detected...
Multi-cancer early detection (MCED) test company Grail (NASDAQ: GRAL) is one of the most fascinating...
Law Offices of Frank R. Cruz Encourages Grail, Inc. (GRAL) Shareholders to Inquire About Securities Fraud Class Action...
GRAIL (NASDAQ:GRAL) said new data presented at the American Society of Clinical Oncology annual meeting showed its Galleri multi-cancer early detection blood test can identify...
Track GRAIL and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to GRAIL and other trending companies.